Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 8/20 | 0.46 |
| ▸ | TTK | P33981 | 1/20 | 0.41 |
| ▸ | IKBKB | O14920 | 3/20 | 0.40 |
| ▸ | CDK11B | P21127 | 2/20 | 0.40 |
| ▸ | CDK7 | P50613 | 2/20 | 0.40 |
| ▸ | CDK13 | Q14004 | 2/20 | 0.40 |
| ▸ | MAP3K19 | Q56UN5 | 2/20 | 0.40 |
| ▸ | MYLK4 | Q86YV6 | 2/20 | 0.40 |
| ▸ | CDK11A | Q9UQ88 | 2/20 | 0.40 |
| ▸ | CHUK | O15111 | 2/20 | 0.37 |
| ▸ | ERN1 | O75460 | 1/20 | 0.37 |
| ▸ | RPS6KA4 | O75676 | 1/20 | 0.37 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.37 |
| ▸ | CDK1 | P06493 | 1/20 | 0.37 |
| ▸ | KIT | P10721 | 1/20 | 0.37 |
| ▸ | CDK2 | P24941 | 1/20 | 0.37 |
| ▸ | TYK2 | P29597 | 1/20 | 0.37 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.37 |
| ▸ | CDK9 | P50750 | 1/20 | 0.37 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL122086 | 0.89 | TTK (0.42) | BRD4TTKIKBKBCDK11BCDK7 | |
| SCHEMBL120582 | 0.88 | BRD4 (0.51) | BRD4TTKIKBKBCDK11BCDK7 | |
| SCHEMBL120811 | 0.87 | BRD4 (0.53) | BRD4TTKIKBKBCDK11BCDK7 | |
| SCHEMBL123549 | 0.87 | BRD4 (0.47) | BRD4TTKIKBKBCDK11BCDK7 | |
| SCHEMBL123312 | 0.87 | BRD4 (0.49) | BRD4TTKIKBKBCDK11BCDK7 | |
| SCHEMBL3723242 | 0.85 | BRD4 (0.49) | BRD4TTKIKBKBCDK11BCDK7 | |
| SCHEMBL6113177 | 0.85 | BRD4 (0.44) | BRD4TTKIKBKBCDK11BCDK7 | |
| SCHEMBL120497 | 0.83 | EPHB4 (0.46) | BRD4TTK | |
| SCHEMBL120707 | 0.83 | TTK (0.47) | BRD4TTKIKBKBCDK11BCDK7 | |
| SCHEMBL13077242 | 0.83 | TTK (0.47) | BRD4TTKIKBKBCDK11BCDK7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8729082-B2 | Substituted imidazoquinoxalines | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-05-20 | — | — | US | claimed |
| US-20120128662-A1 | SUBSTITUTED IMIDAZOQUINOXALINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-05-24 | — | — | US | claimed |
| EP-2424537-A1 | SUBSTITUTED IMIDAZOQUINOXALINES | Bayer Pharma Aktiengesellschaft (DE) | 2012-03-07 | — | — | EP | claimed |
| WO-2010124826-A1 | SUBSTITUTED IMIDAZOQUINOXALINES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-11-04 | — | — | WO | claimed |
| EP-2424537-B1 | SUBSTITUTED IMIDAZOQUINOXALINES | BAYER IP GMBH (DE) | 2015-07-08 | — | — | EP | disclosed |
| EP-2424537-B1 | SUBSTITUTED IMIDAZOQUINOXALINES | BAYER IP GMBH (DE) | 2015-07-08 | — | — | EP | disclosed |
| US-8729082-B2 | Substituted imidazoquinoxalines | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-05-20 | — | — | US | disclosed |
| US-8729082-B2 | Substituted imidazoquinoxalines | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-05-20 | — | — | US | disclosed |
| US-20120128662-A1 | SUBSTITUTED IMIDAZOQUINOXALINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-05-24 | — | — | US | disclosed |
| US-20120128662-A1 | SUBSTITUTED IMIDAZOQUINOXALINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-05-24 | — | — | US | disclosed |
| WO-2010124826-A1 | SUBSTITUTED IMIDAZOQUINOXALINES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120128662-A1 | SUBSTITUTED IMIDAZOQUINOXALINES | TTBK1, TTK, TTBK2 | BRD4 1905/4885TTK 2/4885IKBKB 283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.